Alex Yakobson

Dr. Alex Yakobson


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
AYAlex Yakobson
Alex Yakobson
AJAshraf Abu jama
Ashraf Abu jama
OSOmar Abu Saleh
Omar Abu Saleh
RMRegina Michlin
Regina Michlin
Walid ShalataWalid Shalata
Walid Shalata
Cutaneous squamous cell carcinoma (cSCC) of the skin is the second most common form of skin cancer, with aging and prolonged exposure to ultraviolet rays being the main causes of the disease. Cemiplimab and pembrolizumab recently gained regulatory approval for the treatment of locally advanced and metastatic cSCC—conditions that are not treatable by surgical resection and/or radiotherapy. Although the results from the clinical trials have been promising, these studies have not included immunosuppressed, elderly patients. In this study, we included all immunocompromised and immunocompetent patients over the age of 75 years diagnosed with locally advanced or metastatic cSCC and treated with cemiplimab or pembrolizumab. The median duration of follow-up from cSCC diagnosis was 35.6 months, 82.9% of patients were male, and the median age was 83 years old. The median progression-free survival was 8.94 months. The incidence of treatment-related adverse events was 85.6%, the majority of which were grades 1 or 2. The disease control rate was 91.4%, the complete response rate was 17.1%, the partial response rate was 51.4%, the stable disease rate was 23%, and the progressive disease rate was 8.7%. Based on this study, cemiplimab and pembrolizumab for the treatment of locally advanced or metastatic cSCC in elderly, immunocompromised patients are efficacious, with acceptable safety profiles.

29 July 2023 in Life
Verified
Journal Article
Open access
PDF file
Walid ShalataWalid Shalata
Walid Shalata
AYAlex Yakobson
Alex Yakobson
ACAharon Y. Cohen
Aharon Y. Cohen
IGIris Goldstein
Iris Goldstein
OSOmar Abu Saleh
Omar Abu Saleh
KRKeren Rouvinov
Keren Rouvinov
The introduction of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment standards and significantly enhanced patient prognoses. However, the utilization of these groundbreaking therapies has led to the observation and reporting of various types of adverse events, commonly known as immune-related adverse events (irAEs). In the following article, we present four patients who encountered uncommon toxicities induced by ICIs. The first patient was a 59-year-old female diagnosed with stage 4 lung adenocarcinoma. She received immunotherapy (pembrolizumab) together with chemotherapy and subsequently developed autonomic neuropathy (AN). The next two patients also received chemo-immunotherapy (pembrolizumab) and were both 63-year-old males with stage 4 lung adenocarcinoma. One of the two experienced palmoplantar keratoderma, while the other presented with Reiter’s syndrome (urethritis, conjunctivitis and arthritis). The 4th patient, an 80-year-old male with stage 4 squamous cell carcinoma of the lung, received chemo-immunotherapy (pembrolizumab) and developed myasthenia gravis.

Verified
Journal Article
Open access
PDF file
AYAlex Yakobson
Alex Yakobson
KRKeren Rouvinov
Keren Rouvinov
ACAharon Y. Cohen
Aharon Y. Cohen
IGIris Goldstein
Iris Goldstein
OSOmar Abu Saleh
Omar Abu Saleh
Walid ShalataWalid Shalata
Walid Shalata
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic approach to diverse malignancies, leading to substantial enhancements in patient prognosis. However, along with their benefits, ICIs also increase the incidence of immune-related adverse events (irAEs). In the present paper, we highlight four cases of carpal tunnel syndrome (CTS) as an uncommon manifestation of toxicity induced by ICIs. Although diagnosed with different malignancies, the patients were undergoing ICI therapy when they developed CTS-consistent side effects accompanied by severe neuropathy. Prompt treatment with corticosteroids, intravenous immunoglobulins, or methotrexate resulted in complete symptomatic relief for all patients. This article therefore emphasizes the importance of recognizing and managing rare adverse events associated with ICI use to ensure optimal patient care.

19 July 2023 in Life
Verified
Journal Article
Open access
PDF file
Walid ShalataWalid Shalata
Walid Shalata
ismaell masalhaismaell masalha
ismaell masalha
SIShlomo Yaron Ishay
Shlomo Yaron Ishay
ECElena Chernomordikova
Elena Chernomordikova
AJAshraf Abu jama
Ashraf Abu jama
AYAlex Yakobson
Alex Yakobson
In this particular case study, we present a 66-year-old male who was diagnosed with an atrial myxoma eight years after receiving treatment for non-small cell lung cancer. The patient underwent chemo-radiotherapy (mediastinal area) in 2012 to address stage III-A adenocarcinoma of the lung. During follow-up imaging in 2020, a left atrial mass displaying characteristic features of a cardiac myxoma was detected. Upon reviewing a computed tomographic (CT) scan from 2017 within the previously irradiated mediastinal region, the cardiac mass was retrospectively identified. The surgical excision of the cardiac mass was performed, and a subsequent pathological examination confirmed the diagnosis of myxoma. To the best of our knowledge, this is the first reported case of a left atrial myxoma in a patient previously treated for adenocarcinoma of the lung and the first instance of an atrial myxoma occurring in a site that had undergone prior radiation therapy.

5 September 2023 in Clinics and Practice
Verified
Journal Article
Open access
PDF file
AYAlex Yakobson
Alex Yakobson
ANAla Eddin Neime
Ala Eddin Neime
OSOmar Abu Saleh
Omar Abu Saleh
KAKayed Al Athamen
Kayed Al Athamen
Walid ShalataWalid Shalata
Walid Shalata
Advancements and the use of tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of Chronic Myeloid Leukemia (CML), achieving unprecedented success rates and expanding their applications to various neoplasms. However, the use of TKIs is not without its drawbacks. Skin, gastrointestinal, and central nervous systems are particularly susceptible to adverse effects, including a higher incidence of autoimmune responses in treated individuals. In this report, we present a unique case of bullous pemphigoid, a rare autoimmune disease, which has not been previously associated with TKI therapy as an adverse effect, particularly appearing after discontinuing Imatinib® treatment.